Anyone looking for the next NYR should look at NSB
$5m MC with $5.5m cash and in the same neurological sector.
Trials to start this quarter and was once a 50c stock such was the quality and potential of their lead drug!
This could do the same as NYR on any good news as it sits at a negative EV with a very quality product.
Morning Trading February 29, page-19
-
- There are more pages in this discussion • 289 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)